Irving SivinPekka LähteenmäkiSirpa RantaPhilip DarneyCindy KlaisleLivia WanDaniel R. MishellMaria LacarraOsborn A.C. ViegasPrapas BilhareusSuporn KoetsawangManee Piya-AnantSoledad DiazMargarita PavezFrancisco AlvarezVivian BracheKatherine LaGuardiaHarold NashJanet SternPopulation Council HeadquartersHelsingin YliopistoBellevue Hospital CenterKeck School of Medicine of USCNational University of SingaporeMahidol UniversityInstituto Chileno de Medicina ReproductivaAsoc. Pro Bienstar de la FamiliaWeill Graduate School of Medical Sciences2018-07-042018-07-041997-02-01Contraception. Vol.55, No.2 (1997), 81-85001078242-s2.0-0343683454https://repository.li.mahidol.ac.th/handle/20.500.14594/18168In a three-year randomized trial that included 398 women, blood samples were collected for the purpose of assaying levonorgestrel concentrations in women using a new two-rod contraceptive implant system or an earlier implant formulation, Norplant®-2 implants. Sample collection was at 1, 3, 6, 9, and 12 months after placement and semiannually thereafter through three years. Resulting assays and analyses showed that levonorgestrel concentrations of each implant formulation decreased significantly with time after placement, with increasing body weight, and with ponderal index. In the third year, several measures indicated that concentrations of the contraceptive drug were higher in women using the LNG ROD implants than in users of the original formulation. No pregnancies occurred among women in either group in the three years. This study provides evidence that the minimum levonorgestrel concentration needed to protect against pregnancy is below 200 pg/ml, and possibly is below 175 pg/ml.Mahidol UniversityMedicineArticleSCOPUS10.1016/S0010-7824(96)00276-4